aTyr Pharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ATYR | RNTX | TRAW | SION | HBP.TO | GYRE | |
|---|---|---|---|---|---|---|
| Market cap | 15.45M | 56.82M | 4.13M | 168.41M | 70.27M | 470.79M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | — | -0.1 | -1.7 | -8.4 | 74.0 |
| Price/book | 0.3 | 5.5 | 2.4 | 0.6 | 4.8 | 4.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −79.64% | −57.99% | −86.18% | −89.60% | −54.00% | −39.92% |
| Today | −6.79% | −1.32% | −11.06% | +2.19% | 0.00% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ATYR news ›ATLAUA Launches Botanical Recovery Shot
ATLAUA announced SOLACE, a botanical recovery blend served as a 2fl-oz (59mL) shot. SOLACE launched in November, direct at atlaua.shop and is now open for pre-order. ATLAUA was founded by former professional soccer player Adrian Goransch.…
aTyr Pharma (ATYR) Projected to Release Quarterly Earnings on Thursday
Posted by Michael Walen on Nov 3rd, 2026 aTyr Pharma (NASDAQ:ATYR – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’…
aTyr Pharma Announces One-for-40 Reverse Stock Split
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company ... aTyr Pharma Announces One-for-40 Reverse Stock Split SAN DIEGO, Oct. 27, 2026 (GLOBE…
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis.ATYR0101 is currently u... aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the…
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT⢠Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of…
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026. SAN…
aTyr Pharma, Inc. (ATYR) Stock Analysis: Exploring a Potential 1,458% Upside in the Biotech Sector
In the ever-evolving landscape of biotechnology, aTyr Pharma, Inc. (NASDAQ: ATYR) emerges as an intriguing prospect for investors seeking high-risk, high-reward opportunities. With a staggering potential upside of 1,458.72%, according to…
ATyr Pharma, Inc. Announces CFO Changes
aTyr Pharma, Inc. has announced that Jill Broadfoot, aTyr?s Chief Financial Officer , will step down as of September 30, 2026, and transition to serve as a consultant to the Company. Brandon Yaras,... Published on 08/07/2026 at 04:01 pm…
Transcript : ATyr Pharma, Inc. - Special Call
Presentation Operator MessageOperator Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma conference call. [Operator Instructions] As a reminder, this conference is being recorded Transcript : ATyr Pharma, Inc. - Special…
ATyr Pharma Updates Timing of FDA Response for Planned Phase 3 Trial of Efzofitimod
aTyr Pharma said Tuesday that based on feedback from the US Food and Drug Administration, it now expects to receive a response by mid-September on the protocol it submitted for a planned phase 3... Biotechnology & Medical Research ATyr…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- marketscreener.com6
- stocktitan.net2
- biospace.com1
- directorstalkinterviews.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 20 articles, not a forecast.